DrugPatentWatch Database Preview

TALZENNA Drug Profile

« Back to Dashboard

When do Talzenna patents expire, and what generic alternatives are available?

Talzenna is a drug marketed by Pfizer Inc and is included in one NDA. There are five patents protecting this drug.

This drug has seventy-one patent family members in twenty-seven countries.

The generic ingredient in TALZENNA is talazoparib tosylate. Two suppliers are listed for this compound. Additional details are available on the talazoparib tosylate profile page.

Summary for TALZENNA

International Patents:	71
US Patents:	5
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Clinical Trials:	1
Prior Art and Litigation Support	Order Prior Art and Litigation support for TALZENNA
DailyMed Link:	TALZENNA at DailyMed

Generic Entry Opportunity Date for TALZENNA

NDA:

211651

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TALZENNA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer Inc	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-001	Oct 16, 2018		RX	Yes	No
Pfizer Inc	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-002	Oct 16, 2018		RX	Yes	Yes			Y	Y
Pfizer Inc	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-001	Oct 16, 2018		RX	Yes	No			Y	Y
Pfizer Inc	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-002	Oct 16, 2018		RX	Yes	Yes			Y	Y

International Patents for TALZENNA

Country	Patent Number	Estimated Expiration
Spain	2625817
Brazil	PI0917119
World Intellectual Property Organization (WIPO)	2012054698
Japan	2017061526